Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care ACTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics ...
ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ("Bluejay", "the Company"), a medical diagnostics company focused on developing cost-effective, rapid, ...
This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives ACTON, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bluejay ...
SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphonyâ„¢ IL-6 Test Toward Regulatory Submission ACTON, Mass., October 6, 2026 (Newswire.com) - Bluejay ...
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Bluejay Diagnostics, Inc. (NASDAQ: BJDX) a late-stage, pre-revenue diagnostics company focused on developing ...
Neonatal sepsis is a leading cause of death for newborns Testing IL-6 can indicate a neonatal sepsis infection earlier than other biomarkers Earlier diagnosis of neonatal sepsis can lead to improved ...
RARITAN, N.J., July 22, 2021 /PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced its VITROS (R) ...
BREA, Calif., Oct. 1, 2020 /PRNewswire/ -- Beckman Coulter today announced that it has received Emergency Use Authorization (EUA) for its Access Interleukin-6 (IL-6) assay from the U.S. Food & Drug ...
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported that it has completed 90 subjects in the prospective multicenter ...